{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:18:13Z","timestamp":1791987493161,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007469","name":"Alfred Benzon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Binding Site - Thermo Fischer Scientific"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03028-8","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:55:32Z","timestamp":1783328132000},"page":"2043-2047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Redefining light-chain smoldering multiple myeloma: prevalence and progression risk"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-9330","authenticated-orcid":false,"given":"Cecilie Velsoe","family":"Maeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-3530","authenticated-orcid":false,"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-1166","authenticated-orcid":false,"given":"J\u00f3n \u00de\u00f3rir","family":"\u00d3skarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2162-8414","authenticated-orcid":false,"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00f3rir Einarsson","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten N\u00f8rgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sd\u00eds R.","family":"\u00de\u00f3r\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynjar","family":"Vi\u00f0arsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1ll T.","family":"\u00d6nundarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarni A.","family":"Agnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margr\u00e9t","family":"Sigur\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"\u00deorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cdsleifur","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edas","family":"Ey\u00fe\u00f3rsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sbj\u00f6rn","family":"J\u00f3nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigur\u00f0ur Y.","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"3028_CR1","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390.","journal-title":"N Engl J Med"},{"key":"3028_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsd\u00f3ttir","year":"2023","unstructured":"Thorsteinsd\u00f3ttir S, G\u00edslason GK, Aspelund T, R\u00f6gnvaldsson S, \u00d3skarsson J\u00de, Sigur\u00f0ard\u00f3ttir G\u00c1, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467\u201372.","journal-title":"Nat Med"},{"key":"3028_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjh.14753","volume":"178","author":"JLJ Heaney","year":"2017","unstructured":"Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, et al. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol. 2017;178:220\u201330.","journal-title":"Br J Haematol"},{"key":"3028_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103:506\u201313.","journal-title":"Haematologica"},{"key":"3028_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"3028_CR6","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2016-07-726778","volume":"128","author":"T Dejoie","year":"2016","unstructured":"Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood. 2016;128:2941\u20138.","journal-title":"Blood"},{"key":"3028_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41375-025-02534-5","volume":"39","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, et al. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702. Leukemia. 2025;39:1001\u20134.","journal-title":"Leukemia"},{"key":"3028_CR8","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","volume":"1","author":"RA Kyle","year":"2014","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ, Benson JT, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol. 2014;1:e28\u201336.","journal-title":"Lancet Haematol"},{"key":"3028_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, \u00d3skarsson J\u00de, P\u00e9tursd\u00f3ttir \u00cd, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94.","journal-title":"Blood Cancer J"},{"key":"3028_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00732-3","volume":"12","author":"TE Long","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:133.","journal-title":"Blood Cancer J"},{"key":"3028_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamaoncol.2025.1285","volume":"11","author":"T Einarsson Long","year":"2025","unstructured":"Einarsson Long T, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir IS, Eythorsson E, Oskarsson JT, et al. New definition of light chain monoclonal gammopathy of undetermined significance. JAMA Oncol. 2025;11:753\u201361.","journal-title":"JAMA Oncol"},{"key":"3028_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/CLEP.S479672","volume":"17","author":"C Brieghel","year":"2025","unstructured":"Brieghel C, Werling M, Frederiksen CM, Parviz M, Lacoppidan T, Faitova T, et al. The Danish Lymphoid Cancer Research (DALY-CARE) data resource: the basis for developing data-driven hematology. Clin Epidemiol. 2025;17:131\u201345.","journal-title":"Clin Epidemiol"},{"key":"3028_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01478-y","volume":"16","author":"LS Andersen","year":"2026","unstructured":"Andersen LS, M\u00e6ng CV, R\u00f6gnvaldsson S, Long TE, Brieghel C, Hermansen E, et al. Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification. Blood Cancer J. 2026;16:50.","journal-title":"Blood Cancer J"},{"key":"3028_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03028-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:07:07Z","timestamp":1787641627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03028-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST reports honoraria for scientific presentations from AbbVie, GlaxoSmithKline, Takeda and Thermo Fisher Scientific; advisory board participation for Sanofi; a travel grant from Amgen; and conference participation supported by GlaxoSmithKline outside the submitted work. CVM has participated in a conference supported by Daiichi Sankyo. SR reports honoraria for scientific talks from Johnson & Johnson and Siemens Healthineers. CB has received travel grants from AbbVie and AstraZeneca. CUN has received research funding from AbbVie, Johnson & Johnson, AstraZeneca, the Novo Nordisk Foundation, Genmab, and Octapharma, and has served as a consultant for AbbVie, BeiGene, Janssen, Roche, AstraZeneca, CSL Behring, Genmab, Takeda, Octapharma, MSD, Synamics, and Lilly. KG has received research funding from Janssen. SH is employed at Thermo Fisher Scientific. OL reports grants from Amgen, Johnson & Johnson, and Pfizer; service on independent data monitoring committees for Johnson & Johnson, Takeda, and Merck; and personal fees from Sanofi, Johnson & Johnson, and Pfizer outside the submitted work. SYK reports research funding from Amgen and Celgene and service on an independent data monitoring committee for Johnson & Johnson outside the submitted work. The remaining authors had no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The iStopMM study was approved by the Icelandic National Bioethics Committee (Number 16\u2013022, date: 2016-04-26) and the Icelandic Data Protection Agency and all participants provided informed consent. The study in DALY-CARE was approved by the Danish Health Data Authority (P-2020-561) and National Ethics Committee (1804410). Under Danish legislation, register studies are exempt from informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}